phone icon  Int'l : +1-503-894-6022
Allied Market Research
0
Shopping Cart is Empty..
$ 0

Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective method of treatment with fewer side effects. Current market for cord blood therapeutics accounts for $6.5 billion, which is expected to grow at 33.4% CAGR from 2013-2020. Other segments of this market include - Adult stem cell and embryonic stem cells. Government authorities are supporting the research and clinical trials of cord blood stem cell, which is currently increasing the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. Athersys, California Stem Cell Inc., and Cytori Therapeutics Inc. are engaged in the development of novel stem cell therapies from cord blood. Ethical issues regarding cord blood sample application is creating biasness among donor, which is majorly influencing the market.

Competition is currently intense with companies trying to create brand awareness. This is therefore, compelling the market players to formulate market based strategies. Cord blood stem cell is the only type of stem cell that is stored in controlled condition due to its lower volume higher cell count feature. Storage service market is expected grow at 33.4% CAGR from 2013-2020.

KEY BENEFITS

  • This report provides market intelligence with respect to therapies, applications and storage services in cord blood stem cell market
  • Detailed analysis of top factors influencing the growth of UCB stem cell market so that companies can take developmental decision
  • Value chain analysis, Porters five forces, top investment pockets are analysed and presented in detail in the report
  • Intelligence of important regulatory and reimbursement issues is provided according to geographies so that companies can take strategic decisions
  • SWOT analysis and strategic developments included in the report for Key players: Advanced Cell Technology, Inc. (USA), Athersys, California Stem Cell Inc., Cytori Therapeutics Inc., Mesoblast, Opexa Therapeutics Geron Corporation, Neostem Inc.

KEY MARKET SEGMENTS

GLOBAL MARKET, BY STORAGE

  • Public cord blood banks
  • Private cord blood banks
  • Public Vs. Private UCB banks

GLOBAL MARKET, BY DISEASES

  • Cancer/ Oncology diseases
  • Acute Leukemia
  • Chronic Leukemia
  • High Risk Solid Tumors
  • Myelodysplastic Syndrome
  • Blood diseases
  • Aplastic Anemia
  • Beta Thalassemia
  • Sickle Cell disease
  • Immune Disorders
  • Leukocyte Adhesion Deficiency
  • Hystiocytic Disorders
  • Wiskott-Aldrich
  • Metabolic Disorders
  • Krabbe Disease
  • Hurler Syndrome
  • Sanfilippo Syndrome
  • Other diseases
  • Osteopetrosis
  • Hemophagoyticlymphohistiocytosis

GLOBAL MARKET BY, TECHNOLOGY

  • Stem Cell Transplant
  • Autologous transplant
  • Allogenic transplant
  • Transplant Medicine
  • Regenerative Medicine
  • Others
  • Cord Blood Banking
  • Blood Transfusion
  • Cell Based Genetics

GLOBAL MARKET, BY GEOGRAPHY

  • UCB market in North America
  • UCB market in Europe
  • UCB market in Asia-pacific
  • UCB market in ROW

KEY AUDIENCES

  • Therapeutics service companies
  • Private and government research institutes
  • Academic Institutes
  • Research based pharmaceutical companies
  • Public and Private cord blood banks
* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Title/ Chapter Name

Chapter: 1 INTRODUCTION

1.1 Key objectives
1.2 Key benefits
1.3 Key deliverables
1.4 Key audiences

1.5 Research methodology

1.5.1 Secondary research
1.5.2 Primary research
1.5.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 Umbilical cord blood stem cell market by Geography , 2012-2020, $million

Chapter: 3 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET OVERVIEW

3.1 Market Description
3.2 Market definition and Scope
3.3 Awareness programs for cord blood donation
3.4 Key findings

3.4.1 Top ten factors impacting UCB stem cell market

3.4.1.1 Minimal invasive techniques of collection and transferring
3.4.1.2 Efficient extraction of cord blood
3.4.1.3 Storage service for maintaining viability
3.4.1.4 Government regulation and intervention
3.4.1.5 Ethical issues in storage and application
3.4.1.6 Cost of treatment
3.4.1.7 Availability of treatment and sample
3.4.1.8 Positive engraftment of tissue
3.4.1.9 Efficient transferring during treatment
3.4.1.10 Reimbursement and insurance issues in storage

3.4.2 Top winning strategies
3.4.3 Top Investment pockets

3.4.3.1 UCB stem cell market - by Application
3.4.3.2 UCB market- by Therapeutics
3.4.3.3 UCB market- by Storage service

3.5 Advantages of umbilical cord blood stem cells over peripheral blood stem cells
3.6 Key advantages of UCB stem cells.

3.6.1 Prompt availability
3.6.2 Ease of collection
3.6.3 More tolerance for graft failure
3.6.4 Reduce risk of Graft vs. host disease (GVHD)
3.6.5 Decreased transmission of viral disease infection

3.7 Regulatory issues, legislations and authorities Reimbursement Issues

3.7.1 Regulatory issues of UCB stem cells storage and application (U.S.)

3.7.1.1 American Academy of Pediatrics (AAP)
3.7.1.2 American society for Blood and Marrow Transplantation (ASBMT)

3.7.2 Regulatory issues concenringUCB stem cells storage and application in European countries
3.7.3 Reimbursement issues

3.8 Ethical issues of stem cell therapies and cord blood banking

3.8.1 Ethical issues regarding cord blood banking
3.8.2 Ethical issues in cord blood stem cell therapies

3.9 Umbilical cord blood stem cell collection process
3.10 UCB Stem cells Storage and collection Outsourcing

3.10.1 Stem cell storage and collection outsourcing

3.10.1.1 Criteria for outsourcing of cord blood storage

3.11 Key patents and analysis of Novel Patents
3.12 Clinical trials in UCB stem cell market

3.12.1 Phase 2 Study of stem cell Educator Therapy in Type 1 Diabetes
3.12.2 Safety of Autologous Human Umbilical Cord Blood in the Treatment of Stroke in Children
3.12.3 Longitudinal Study of Immune Mediated Disorders After AllogenicHematopoietic Cell Transplantation (HCT)
3.12.4 Evaluation of Hematopoietic and Immunologic Reconstitution after a Reduced-intensity Conditioning Regimen
3.12.5 Umbilical Cord Blood Transplant for Congenital Pediatrics Disorders

3.13 Value chain analysis of UCB stem cell market
3.14 Porter’s five forces analysis for cord blood stem cell market

3.14.1 Higher bargaining power of suppliers for getting competitive advantage
3.14.2 Lower bargaining power of buyers in terms of treatment
3.14.3 Higher degree of competition
3.14.4 Threats of new entrants increases due to novel therapies
3.14.5 Increased threats fromconventional therapies and banking substitutes

 3.15 Market Dynamics of UCB stem cell market

3.15.1 Market Drivers

3.15.1.1 Minimal invasive methods
3.15.1.2 Treatment on chronic diseases
3.15.1.3 Cost effective therapy and storage
3.15.1.4 Easy extraction methods
3.15.1.5 Intact genetic structure

3.15.2 Market Restraints

3.15.2.1 Government regulations and intervention
3.15.2.2 Legal and ethical issues during collection
3.15.2.3 Availability of right type of donor
3.15.2.4 Higher cost of therapies

3.15.3 Market Opportunities

3.15.3.1 Advancement in therapeutic application
3.15.3.2 Rising funds for public storage
3.15.3.3 Increase in cost effectiveness to increase APAC market presence

Chapter: 4 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY STORAGE SERVICE

4.1 Difference between Public vs. Private UCB banks

4.1.1 Umbilical cord blood stem cell storage service market ,2012-2020, $million

4.2 Market Drivers

4.2.1 Lower cost structure
4.2.2 Immediate availability
4.2.3 Government Intervention
4.2.4 Decrease transplant complications

4.3 Market Restraints

4.3.1 Long term storage
4.3.2 Lower volume of blood
4.3.3 Operational Issues
4.3.4 Legal & Ethical Issues

4.4 Market Opportunities

4.4.1 Additional fund collection
4.4.2 Technological adoptions
4.4.3 Insurance as USP
4.4.4 Lowering healthcare costs

4.5 Public cord blood banks

4.5.1 Cost structure of public cord blood banking:
4.5.2 UCB public storage bank service market , 2012-2020, $million

4.6 Private cord blood banks

4.6.1 UCB private storage bank service market, 2012-2020, $million

Chapter: 5 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY THERAPEUTICS

5.1 Umbilical cord blood stem cell therapeutics market , 2012-2020, $million
5.2 Market Drivers

5.2.1 Fast recovery
5.2.2 Efficient transferring of stem cells
5.2.3 Minimum invasive technique
5.2.4 Target specific

5.3 Market Restraints

5.3.1 Higher cost of treatment
5.3.2 Scarcity of donor
5.3.3 Rejection in allogenictransplantation
5.3.4 Difficulty in donor matching

5.4 Opportunities

5.4.1 Increasing flexibility
5.4.2 Improved donor policy
5.4.3 Risk management

5.5 Cancer/ Oncology diseases

5.5.1 UCB stem cell cancer therapeutics geography market , 2012-2020, $million
5.5.2 UCB stem cell cancer therapeutics market , 2012-2020, $million
5.5.3 Acute Leukemia
5.5.4 UCB stem cell Acute leukemia therapeutics market , 2012-2020,$million
5.5.5 Chronic Leukemia
5.5.6 GLOBAL UCB stem cell Chronic leukemia therapeutics market , 2012-2020, $million
5.5.7 High risk solid tumours
5.5.8 Global UCB stem cell high risk solid tumor therapeutics market , 2012-2020, $million
5.5.9 Myelodysplastic syndrome
5.5.10 Global UCB stem cell Myleodysplastic syndrome (MDS) therapeutics market , 2012-2020,$million
5.5.11 Others(chronic myelomonocyticleukemia (CMML))
5.5.12 UCB stem cell other disease therapeutics geography market , 2012-2020, $million

 5.6 Diabetes

5.6.1 Global UCB stem cell diabetes therapeutics market , 2012-2020, $million
5.6.2 Global UCB stem cell diabetes therapeutics geography market , 2012-2020, $million
5.6.3 Type 1 diabetes
5.6.4 Global UCB stem cell type I diabetes therapeutics geography market, 2012-2020, $million
5.6.5 Type 2 diabetes
5.6.6 UCB stem cell Type II diabetes therapeutics geography market , 2012-2020, $million
5.6.7 Others(Gestational Diabetes Mellitus (GDM)
5.6.8 UCB stem cell Gestational Diabetes Mellitus (GDM) therapeutics geography market , 2012-2020, $million

5.7 Blood diseases

5.7.1 UCB stem cell blood diseases therapeutics market , 2012-2020, $million
5.7.2 UCB stem cell blood diseases therapeutics geography market, 2012-2020, $million
5.7.3 Aplastic Anemia
5.7.4 Global UCB stem cell Aplastic anemia therapeutics geography market 2012-2020, $million
5.7.5 Beta Thalassemia
5.7.6 Global UCB stem cell Thalassemia therapeutics geography market , 2012-2020, $million
5.7.7 Sickle Cell disease
5.7.8 Global UCB stem cell Sickle cell disease therapeutics geography market 2012-2020, $million
5.7.9 Others (Iron deficiency anemia)
5.7.10 Global UCB stem cell others disease therapeutics geography market , 2012-2020, $million

5.8 Immune Disorders

5.8.1 Global UCB stem cell immune disorders therapeutics market , 2012-2020, $million
5.8.2 Global UCB stem cell immune disorders therapeutics geography market , 2012-2020, $million
5.8.3 Leukocyte Adhesion Deficiency
5.8.4 Global UCB stem cell Leukocyte Adhesion deficiency therapeutics geography market , 2012-2020, $million
5.8.5 Hystiocytic disorders
5.8.6 Global UCB stem cell Hystiocytic disorders therapeutics geography market 2012-2020, $million
5.8.7 Wiskott-Aldrich
5.8.8 Global UCB stem cell Wiskott-Aldrich therapeutics geography market 2012-2020, $million
5.8.9 Others(Inflammatory Bowel Disease (IBD) and Multiple Sclerosis(MS)
5.8.10 Global UCB stem cell others disease therapeutics geography market , 2012-2020, $million

5.9 Metabolic Disorders

5.9.1 Global UCB stem cell metabolic disorders therapeutics market , 2012-2020, $million
5.9.2 Global UCB stem cell metabolic disorders therapeutics geography market , 2012-2020, $million
5.9.3 Krabbe Disease
5.9.4 Global UCB stem cell Krabbe disease therapeutics geography market , 2012-2020, $million
5.9.5 Hurler Syndrome
5.9.6 Global UCB stem cell Hurler syndrome therapeutics geography market , 2012-2020, $million
5.9.7 Sanfilippo Syndrome
5.9.8 Global UCB stem cell Sanfilippo Syndrome therapeutics geography market , 2012-2020, $million
5.9.9 Others (Fabry disease)
5.9.10 Global UCB stem cell Fabry disease therapeutics geography market , 2012-2020, $million

5.10 Other diseases

5.10.1 Global UCB stem cell other disease therapeutics market 2012-2020, $million
5.10.2 Osteopetrosis
5.10.3 Global UCB stem cell Osteopetrosis disease therapeutics geography market, 2012-2020, $million
5.10.4 Hemophagoyticlymphohistiocytosis (HLH)
5.10.5 Global UCB stem cell Hemophagoytic lymphohistiocytosis therapeutics geography market , 2012-2020, $million

Chapter: 6 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY APPLICATION

6.1 Umbilical cord blood stem cell application market , 2012-2020, $million
6.2 Drivers of UCB stem cell application market

6.2.1 Auto-repair process
6.2.2 Pre-surgery management
6.2.3 Disease information
6.2.4 Positive engraftment

6.3 Restraints of UCB stem cell application market

6.3.1 Higher cost of treatment
6.3.2 Genetic variation
6.3.3 Donor Matching
6.3.4 Ethical problem

6.4 Opportunity of UCB stem cell application market

6.4.1 Cost effective regenerative medicines
6.4.2 Wound management therapies
6.4.3 Growing research institute

6.5 Stem Cell Transplant

6.5.1 Global UCB stem cell transplant application market , 2012-2020, $million
6.5.2 Autologous transplant
6.5.3 Global UCB stem cell autologous transplant applicationgeogrpahy market 2012-2020, $million
6.5.4 Allogenictransplant
6.5.5 Global UCB stem cell allogenic transplant application geography market , 2012-2020, $million

6.6 Transplant Medicine

6.6.1 Global UCB stem cell transplant medicine application geography market , 2012-2020, $million

6.7 Regenerative Medicine

6.7.1 Global UCB stem cell regenerative medicine application geography market , 2012-2020, $million

6.8 Others

6.8.1 Global UCB stem cell other diseases application market , 2012-2020, $million
6.8.2 Blood Transfusion
6.8.3 Global UCB stem cell blood tranfusion application geography market 2012-2020, $million
6.8.4 Cell Based Genetics
6.8.5 Global UCB stem cell based genetics application geography market , 2012-2020, $million

Chapter: 7 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY GEOGRAPHY

7.1 Umbilical cord blood stem cell market by geography , 2012-2020, $million
7.2 UCB stem cell market in North America
7.3 UCB stem cell market in Europe
7.4 UCB stem cell market in Asia-Pacific
7.5 UCB market in ROW

Chapter: 8 COMPANY PROFILES

8.1 Cytori Therapeutics Inc.

8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Key Financials of Cytori Therapeutics Inc.
8.1.4 Key Strategies of Cytori Therapeutics Inc.

8.1.4.1 Primary Strategies: Approval
8.1.4.2 Secondary Strategies: Product Launch and Clinical trials

8.1.5 SWOT AnalysisofCytori Therapeutics Inc.

8.2 Advanced Cell Technology, Inc. (USA)

8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Key Financials Advanced Cell Technology, Inc. (USA)
8.2.4 Key Strategies Advanced Cell Technology, Inc. (USA)

8.2.4.1 Primary Strategies: Approval
8.2.4.2 Secondary strategies: Study Report

8.2.5 SWOT Analysis Advanced Cell Technology, Inc. (USA)

8.3 California Stem Cell

8.3.1 Company Overview
8.3.2 Company Snapshot:
8.3.3 Key Strategies California Stem Cell

8.3.3.1 Primary Strategies: Approval
8.3.3.2 Secondary Strategies: Acquisition and clinical trials

8.3.4 SWOT Analysis of California Stem Cell

8.4 Osiris Therapeutics

8.4.1 Company Overview
8.4.2 Company Snapshot:
8.4.3 Key Financials Osiris Therapeutics
8.4.4 Key Strategies Osiris Therapeutics

8.4.4.1 Primary Strategies: Approval
8.4.4.2 Secondary strategies: Clinical Trials

8.4.5 SWOT analysis of Osiris therapeutics

8.5 NeoStem Inc.

8.5.1 Company Overview
8.5.2 Company Snapshot:
8.5.3 Key Financials NeoStem Inc.
8.5.4 Key Strategies NeoStem Inc.

8.5.4.1 Primary Strategies: Clinical Trials
8.5.4.2 Secondary Strategies: Collaboration

8.5.5 SWOT AnalysisofNeoStem Inc.

8.6 Geron Corporation

8.6.1 Company Overview
8.6.2 Company Snapshot:
8.6.3 Key Financials Geron Corporation
8.6.4 Key Strategies Geron Corporation

8.6.4.1 Primary Strategies: Clinical Trials and Investment
8.6.4.2 Secondary Strategies: Collaboration

8.6.5 SWOT Analysis of Geron Corporation

8.7 Opexa Therapeutics, Inc.

8.7.1 Company Overview
8.7.2 Company Snapshot:
8.7.3 Key Strategies Opexa Therapeutics, Inc.

8.7.3.1 Primary Strategies: Approval
8.7.3.2 Secondary Strategies: Agreement

8.7.4 SWOT Analysis of Opexa Therapeutics, Inc.

8.8 Athersys, Inc.

8.8.1 Company Overview
8.8.2 Company Snapshot:
8.8.3 Key Financials of Athersys, Inc.
8.8.4 Key Strategies Athersys, Inc.

8.8.4.1 Primary Strategies: Clinical Trials
8.8.4.2 Secondary Strategies: Collaboration

8.8.5 SWOT Analysis Athersys, Inc.

8.9 Pluristem Therapeutics Inc.

8.9.1 Company Overview
8.9.2 Company Snapshot:
8.9.3 Key FinancialsPluristem Therapeutics Inc.
8.9.4 Key Strategies Pluristem Therapeutics Inc.

8.9.4.1 Primary Strategies: Approval& Clearance
8.9.4.2 Secondary Strategies: Product Launch

8.9.5 SWOT Analysis of Pluristem Therapeutics Inc.

8.10 Mesoblast Limited

8.10.1 Company Overview
8.10.2 Company Snapshot:
8.10.3 Key Financials of Mesoblast Limited
8.10.4 Key Strategies of Mesoblast Limited

8.10.4.1 Primary Strategies: Acquisition
8.10.4.2 Secondary Strategies: Approval
8.10.5 SWOT Analysis ofMesoblast Limited

 

LIST OF TABLES:

TABLE 1    UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLION
TABLE 2    DIFFERENCE BETWEEN PERIPHERAL BLOOD AND CORD BLOOD
TABLE 3   CLINICAL TRIALS PHASE 2 STUDY OF STEM CELL EDUCATOR THERAPY IN TYPE 1 DIABETES
TABLE 4    UMBILICAL CORD BLOOD STEM CELL STORAGE SERVICE MARKET ,2012-2020, $MILLION
TABLE 5    PRICING STRUCTURE OF XYTEXCRYO INTERNATIONAL CORD BLOOD BANK
TABLE 6    PRICING STRUCTURE OF PARENT’S GUIDE TO CORD BLOOD FOUNDATION
TABLE 7    UCB PUBLIC STORAGE BANK SERVICE MARKET , 2012-2020, $MILLION
TABLE 8    PRICING CHART FOR DIFFERENT PRIVATE CORD BLOOD BANKS
TABLE 9    UCB PRIVATE STORAGE BANK SERVICE MARKET ,2012-2020, $MILLION
TABLE 10    NUMBER OF TRANSPLANT BY NEW YORK BLOOD CENTER (2009)
TABLE 11    EMERGING THERAPIES FROM CORD BLOOD STEM IN CHILDREN (2012)
TABLE 12    UMBILICAL CORD BLOOD STEM CELL THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 13    UCB STEM CELL CANCER THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 14    UCB STEM CELL CANCER THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 15    UCB STEM CELL ACUTE LEUKEMIA THERAPEUTICS MARKET , 2012-2020,$MILLION
TABLE 16    GLOBAL UCB STEM CELL CHRONIC LEUKEMIA THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 17    GLOBAL UCB STEM CELL HIGH RISK SOLID TUMOR THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 18    GLOBAL UCB STEM CELL MYLEODYSPLASTIC SYNDROME (MDS) THERAPEUTICS MARKET , 2012-2020,$MILLION
TABLE 19    UCB STEM CELL OTHER DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 20    GLOBAL UCB STEM CELL DIABETES THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 21    GLOBAL UCB STEM CELL DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 22    GLOBAL UCB STEM CELL TYPE I DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 23    UCB STEM CELL TYPE II DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 24    UCB STEM CELL GESTATIONAL DIABETES MELLITUS(GDM) THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 25    UCB STEM CELL BLOOD DISEASES THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 26    UCB STEM CELL BLOOD DISEASES THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLION
TABLE 27    GLOBAL UCB STEM CELL APLASTIC ANEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 28    GLOBAL UCB STEM CELL THALASSEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 29    GLOBAL UCB STEM CELL SICKLE CELL DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 30    GLOBAL UCB STEM CELL OTHERS DIESEA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 31    GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 32    GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 33    GLOBAL UCB STEM CELL LEUKOCYTE ADHESION DEFICIENCY THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 34    GLOBAL UCB STEM CELL HYSTIOCYTIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET 2012-2020, $MILLION
TABLE 35    GLOBAL UCB STEM CELL WISKOTT-ALDRICH THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 36    GLOBAL UCB STEM CELL OTHERS.DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 37    GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 38    GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 39    GLOBAL UCB STEM CELL KRABBE DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 40    GLOBAL UCB STEM CELL HURLER SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 41    GLOBAL UCB STEM CELL SANFILIPPO SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 42    GLOBAL UCB STEM CELL FABRY DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 43    GLOBAL UCB STEM CELL OTHER DISEASE THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 44    GLOBAL UCB STEM CELL OSTEOPETROSIS DISEASE THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLION
TABLE 45    GLOBAL UCB STEM CELL HEMOPHAGOYTIC LYMPHOHISTIOCYTOSIS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 46    UMBILICAL CORD BLOOD STEM CELL APPLICATION MARKET , 2012-2020, $MILLION
TABLE 47    GLOBAL UCB STEM CELL TRANSPLANT APPLICATION MARKET , 2012-2020, $MILLION
TABLE 48    GLOBAL UCB STEM CELL TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 49    GLOBAL UCB STEM CELL AUTOLOGOUS TRANSPLANT APPLICATIONGEOGRPAHY MARKET , 2012-2020, $MILLION
TABLE 50    GLOBAL UCB STEM CELL ALLOGENIC TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 51    GLOBAL UCB STEM CELL TRANSPLANT MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 52    GLOBAL UCB STEM CELL REGENERATIVE MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 53    GLOBAL UCB STEM CELL OTHER DISEASES APPLICATION MARKET , 2012-2020, $MILLION
TABLE 54    GLOBAL UCB STEM CELL BLOOD TRANFUSION APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 55    GLOBAL UCB STEM CELL BASED GENETICS APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 56    COMPARATIVE ANALYSIS OF MARKET BY GEOGRAPHY
TABLE 57    UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLION
TABLE 58    CYTORI THERAPEUTICS INC(USA) COMPANY SNAPSHOT
TABLE 59    ADVANCED CELL TECHNOLOGIES INC. COMPANY SNAPSHOT
TABLE 60    CALIFORNIA STEM CELL INC. COMPANY SNAPSHOT
TABLE 61    OSIRIS THERAPEUTICS COMPANY SNAPSHOT
TABLE 62    NEOSTEM INC COMPANY SNAPSHOT
TABLE 63    GERON CORPORATION COMPANY SNAPSHOT
TABLE 64    OPEXA THERAPEUTICS, INC. COMPANY SNAPSHOT
TABLE 65    ATHERSYS INC. COMPANY SNAPSHOT
TABLE 66    PLURISTEM THERAPEUTICS INC. COMPANY SNAPSHOT
TABLE 67    MESOBLAST LIMITED COMPANY SNAPSHOT

 

LIST OF FIGURES:

FIG. 1    SUCCESS RATE FOR UCB STEM CELL TRANSPLANT BASED ON TYPE OF DONORS (2012)
FIG. 2    UCB STEM CELL MARKET DEFINITION
FIG. 3    PERCENTAGE OF WOMEN TAKING PRESCRIPTION BY PHYSICIANS (2007-2012)
FIG. 4    FACTORS IMPACTING ON UCB STEM CELL MARKET
FIG. 5    TOP WINING STRATEGIES FOR UCB STEM CELL MARKET FROM 2008-2013
FIG. 6    TOP INVESTMENT POCKETS IN UCB CORD BLOOD STEM CELL APPLICATION MARKET (2012-2020)
FIG. 7    PERCENTAGE COMPARISON OF CAGR IN THERAPEUTICS MARKET
FIG. 8    PERCENTAGE COMPARISON OF  CAGR IN STORAGE SERVICE MARKET
FIG. 9    CORD BLOOD STEM CELL COLLECTION PROCEDURE
FIG. 10    KEY PATENTS FOR UCB STEM CELL FROM 2008-2013
FIG. 11    PATENT ANALYSIS FROM 2008-2013
FIG. 12    VALUE CHAIN ANALYSIS OF UCB STEM CELL MARKET
FIG. 13    PORTER FIVE FORCE MODEL FOR CORD BLOOD STEM CELL MARKET
FIG. 14    IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS IN UCB STEM CELL MARKET
FIG. 15    CORD BLOOD UNITS ON THE MATCH REGISTRY (2013)
FIG. 16    GROWTH IN DISEASE TREATED VS. CLINICAL TRIALS (2008-2012)
FIG. 17    AGE GROUP TREATED WITH CORD BLOOD STEM CELL THERAPIES
FIG. 18    TOP 10 COUNTRIES IN CANCER POPULATION (PER 100,000 PEOPLE) 2011
FIG. 19    CANCER STATISTICS FOR ESTIMATED NEW CASES AND DEATHS IN U.S. FOR 2012
FIG. 20    SUBTYPES OF LEUKEMIA CASES IN CHILDREN WORLD-WIDE (2013)
FIG. 21    CHRONIC DISEASE BURDEN 2003-2023 ($ BILLIONS)
FIG. 22    NUMBER OF AMERICANS WITH CHRONIC DISEASES(FORECASTED)
FIG. 23    TREATMENT THERPAIES ON DIABETES, 2011
FIG. 24    PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY,IN 2012(IN THOUSANDS)
FIG. 25    GLOBAL PREVALENCE OFTYPE-2 DIABETES IN 2000 &ESTIMATED PREVALENCE IN 2030
FIG. 26    SINGAPORE CORD BLOOD BANK INVENTORY AND TRANSPLANT (2005-2013)
FIG. 27    STEM CELL TRANSPLANT BY CELL SOURCE IN CHILDREN BELOW 18 YEARS
FIG. 28    IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS OF UCB STEM CELL APPLICATION MARKET
FIG. 29    EMERGING APPLICATION OF CORD BLOOD UNITS IN 2012
FIG. 30    TRANSFORMATION OF CORD BLOOD STEM CELL APPLICATION IN REGENERATIVE MEDICINE APPLICATION
FIG. 31    GROWTH RATE COMPARISON FOR UCB STEM CELLGEOGRAPHY MARKET (2013-2020)
FIG. 32    U.S. FEDRAL SPENDING -FISCAL YEAR 2012
FIG. 33    CONCENTRATION OF EUROPEAN STEM CELL THERAPY FIRMS
FIG. 34    TOTAL CELL THERAPIES BY TYPES IN EUROPEAN COUNTRIES
FIG. 35    DISEASES FACED OR IN FAMILY MEMBERS IN CHINA
FIG. 36    SWOT ANALYSIS OF CYTORI THERAPEUTICS INC.
FIG. 37    SWOT ANALYSIS OF ADVANCED CELL TECHNOLOGY, INC. (USA)
FIG. 38    SWOT ANALYSIS OF CALIFORNIA STEM CELL
FIG. 39    SWOT ANALYSIS OSIRIS THERAPEUTICS
FIG. 40    SWOT ANALYSISOFNEOSTEM INC.
FIG. 41    SWOT ANALYSISOFGERONCORPORATION
FIG. 42    SWOT ANALYSIS OF OPEXA THERAPEUTICS, INC
FIG. 43    SWOT ANALYSIS OF ATHERSYS, INC.
FIG. 44    SWOT ANALYSIS OF PLURISTEM THERAPEUTICS INC.
FIG. 45    SWOT ANALYSIS FOR MESOBLAST LIMITED

Cord blood stem cell collection is much easier way of obtaining stem cell as compared to other stem cells such as Bone Marrow. Minimal invasive technique in stem cell collection and transferring is yet to saturate as this market is emerging in therapeutics. Minimal invasive techniques are available for collection of cord blood however; there is need to conduct some surgical operation in transferring of stem cells. These techniques are expected to become non-invasive in future.


This market research report is an effort to provide the clear picture of the state of the market and sub markets over the next seven years. The report provides micro level analysis of the factors affecting the market, key market trends and industry drives and challenges for the better understanding of the market structure. The presentation of the market dynamics, competitive scenario and developments will enable marketers to aptly design their growth strategies and have competitive edge. Moreover, assessment of the top investment pockets and winning strategies will help in channelizing their investments in the right directions to garner better proceeds.

SINGLE USER
GROUP LICENSE
SITE LICENSE
GLOBAL LICENSE
$4515
$5325
$7350
$10680
LICENSE INFO
Users/Sharing
Restricted to one authorized user

Limited to 5 authorized users

Up to 25 users


unlimited within company / enterprise
Copy/Paste
Allowed up to 20% of the content
Allowed up to 25% of the content
Allowed up to 50% of the content
allowed 100%

Printing
One print only

Five Prints

Unlimited for internal use
Unlimited for internal use
Delivery Formats
ADDED BENIFITS
20% Free customization (Pre-sale)
16 Analyst hour support (Post Sale)
40 Analyst hour support (Post Sale)
160 hours of mini-consult
Free quarterly industry update
Free report on update (within 180 days)
MULTIPLE PURCHASE
Complimentary report with 2 reports
Complimentary report with 3 reports
Subscription Model
Have questions ?
connect
Need to add more ?
request

Single User
$4515
Group User
$5325
Site User
$7350
Global User
$10680
buy now

Discount will be applied in cart.
First time buyer ?
Check offers and discount
on this report
GET DISCOUNT
Need More Information
phone_n +1-503-894-6022

Help AMR help@alliedmarketresearch.com
Or
Send Enquiry
WHY ALLIED MARKET RESEARCH?
Infallible Methodology
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader
RECENTLY VIEWED REPORTS
get_n
SIMILAR MARKET REPORTS
  • ...
    Synthetic biology is a novel field that finds its origin at the intersection of biology and engineering. It involves designing and construction of biological systems or devices that can be applied in varied domains to get specified results. Its a multidisciplinary effort made by scientists to understand the functioning of biological organisms, cells & genes and implementation of artificial genetic processes to give specific characteristics to an organism. It can even be used to develop a completely new biological system. Global synthetic biology market was valued at $3.0 billion in 2013 and it is estimated to reach $38.7 billion by 2020, growing at a CAGR of 44.2% during the forecast period.
    May 2014 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Nonalcoholic Steatohepatitis (NASH) also known as silent disease is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication.
    Aug 2014 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    DNA diagnostics is a cutting edge method which is set to revolutionize the field of medical diagnostics. This technique enables medical professionals to identify various diseases, such as cancer, infectious diseases, and myogenic disorders, and to determine the appropriate treatment for the same. It is also used for clinical diagnostic confirmation and in prenatal diagnostics.
    Aug 2014 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    In vitro diagnostics (IVD) are diagnostic tests practiced in an artificial environment. The overall revenue of the Asia-Pacific IVD market accounted for about $10.7 billion in 2014, and is estimated to reach $15.3 billion by 2020.
    Mar 2016 | Price: $2850(SU) €0(SU) £0(SU) | View Details >>
ON DEMAND REPORTS
  • ...
    Revenue cycle management (RCM) system is used for tracking financial records in healthcare facilities. The system includes tracking from registration and appointment to final payment of services. It integrates business sides and clinical sides, such as personal information of patients, insurance provider, and treatment received by patients.
    Jul 2016 | View Details >>
  • ...
    Negative Pressure Wound Therapy is a devise based technology used for healing wounds by providing a moist healing environment. It is used in the treatment of both acute and chronic wounds. Chronic wounds are difficult to heal and thus require special treatment. This non-invasive therapy system uses sub-atmospheric pressure to remove fluid and infectious material from the wound and provides moist healing environment to the wound to promote faster healing.
    Jul 2016 | View Details >>
  • ...
    Antibody drug conjugates (ADCs), also known as anti-cancer drugs are promising and effective modalities for cancer therapies. The ADCs are prepared by combining two principles i.e. monoclonal antibody specificity and cell killing efficacy of HPAPI (highly potent active pharmaceutical ingredient). This combinational approach specifically kills the cancer cells by a toxic payload through binding and internalizing ADC into the cancerous cells. Several years of extensive biological research
    Jul 2016 | View Details >>
  • ...
    Metabolomics is the study of chemical processes which involve metabolites. Metabolites are small molecules present in the blood, tissues and urine. Metabolomics pertains to the study of the unique chemical fingerprints left behind by cellular processes. These metabolite fingerprints could be used to learn about the health of an organism. It is an upcoming technology in the field of analytical biochemistry.
    Jul 2016 | View Details >>